From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Causes | t − 1 n (%) | t − 2 n (%) |
---|---|---|
Administrative barriers/health insurance company did not authorize | 3 (37.5) | 1 (6.67) |
Adverse event | 3 (37.5) | 3 (20) |
Worsening of symptoms/therapy change | 1 (12.5) | – |
Suspended by -pulmonologist decision (no explicit reason) | 1 (12.5) | – |
Suspended by allergologist decision (no explicit reason) | – | 3 (20) |
Distant home | – | 2 (13.3) |
Asthma exacerbation | – | 1 (6.7) |
Diagnosis and treatment of cancer | – | 1 (6.7) |
Weight gain | – | 1 (6.7) |
No response to treatment | – | 1 (6.7) |
Persistency of shortness of breath and wheezing | – | 1 (6.7) |
Improvement and the need of provocation tests | – | 1 (6.7) |